H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUP: